NasdaqGM - Nasdaq Real Time Price USD

SI-BONE, Inc. (SIBN)

Compare
13.80
-0.56
(-3.90%)
As of 12:46:32 PM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Jeffrey W. Dunn Executive Chairman 290.74k -- 1956
Ms. Laura A. Francis MBA CEO & Director 1.26M -- 1967
Mr. Anshul Maheshwari Chief Financial Officer 705.69k -- 1980
Mr. Anthony J. Recupero President of Commercial Operations 902.11k -- 1959
Dr. Scott A. Yerby Senior VP of Engineering & CTO -- -- 1968
Saqib Iqbal Director of FP&A and Investor Relations -- -- --
Mr. Michael A. Pisetsky J.D. Chief Business & Legal Affairs Officer, Secretary and General Counsel -- -- 1978
Mr. Troy Wahlenmaier Senior Vice President of US Sales -- -- --
Ms. Joyce Goto VP & Corporate Controller -- -- 1974

SI-BONE, Inc.

471 El Camino Real
Suite 101
Santa Clara, CA 95050
United States
408 207 0700 https://si-bone.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
349

Description

SI-BONE, Inc., a medical device company, focuses on solving musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. The company offers proprietary minimally invasive surgical implant systems to address sacroiliac joint dysfunction and degeneration, adult deformity and degeneration, and pelvic trauma, as well as implantable bone products. It also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with a proprietary 3D-printed porous surface and fenestrated design; iFuse TORQ, a line of 3D-printed threaded implants designed for applications in pelvic trauma and sacroliliac fusion; and iFuse Bedrock Granite Implant System that provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion; and iFuse TORQ TNT to treat pelvic trauma and sacroiliac joint dysfunction, as well as iFuse INTRA implants that are marketed as human cells, tissues, and cellular or tissue-based products. The company markets its products primarily with a direct sales force, as well as through third-party sales agent and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

Corporate Governance

SI-BONE, Inc.’s ISS Governance QualityScore as of April 1, 2025 is 6. The pillar scores are Audit: 3; Board: 6; Shareholder Rights: 8; Compensation: 5.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

May 5, 2025 at 10:59 AM UTC - May 9, 2025 at 12:00 PM UTC

SI-BONE, Inc. Earnings Date

Recent Events

February 25, 2025 at 12:00 AM UTC

S-8: Offering Registrations

February 24, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

January 13, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 12, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

August 6, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

August 5, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

July 19, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

June 26, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 7, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

May 6, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers